Hemodynamic and anti-inflammatory effects of early esmolol use in hyperkinetic septic shock: a pilot study

Bruno Levy, Caroline Fritz, Caroline Piona, Kevin Duarte, Andrea Morelli, Philippe Guerci, Antoine Kimmoun, Nicolas Girerd, Bruno Levy, Caroline Fritz, Caroline Piona, Kevin Duarte, Andrea Morelli, Philippe Guerci, Antoine Kimmoun, Nicolas Girerd

Abstract

Background: Several studies have shown that heart rate control with selective beta-1 blockers in septic shock is safe. In these trials, esmolol was administered 24 h after onset of septic shock in patients who remained tachycardic. While an earlier use of beta-blockers might be beneficial, such use remains challenging due to the difficulty in distinguishing between compensatory and non-compensatory tachycardia. Therefore, the Esmosepsis study was designed to study the effects of esmolol aimed at reducing the heart rate by 20% after the initial resuscitation process in hyperkinetic septic shock patients on (1) cardiac index and (2) systemic and regional hemodynamics as well as inflammatory patterns.

Methods: Nine consecutive stabilized tachycardic hyperkinetic septic shock patients treated with norepinephrine for a minimum of 6 h were included. Esmolol was infused during 6 h in order to decrease the heart rate by 20%. The following data were recorded at hours H0 (before esmolol administration), H1-H6 (esmolol administration) and 1 h after esmolol cessation (H7): systolic arterial pressure, diastolic arterial pressure, mean arterial pressure, central venous pressure, heart rate, PICCO transpulmonary thermodilution, sublingual and musculo-cutaneous microcirculation, indocyanine green clearance and echocardiographic parameters, diuresis, lactate, and arterial and venous blood gases.

Results: Esmolol was infused 9 (6.4-11.6) hours after norepinephrine introduction. Esmolol was ceased early in 3 out of 9 patients due to a marked increase in norepinephrine requirement associated with a picture of persistent cardiac failure at the lowest esmolol dose. For the global group, during esmolol infusion, norepinephrine infusion increased from 0.49 (0.34-0.83) to 0.78 (0.3-1.11) µg/min/kg. The use of esmolol was associated with a significant decrease in heart rate from 115 (110-125) to 100 (92-103) beats/min and a decrease in cardiac index from 4.2 (3.1-4.4) to 2.9 (2.5-3.7) l/min/m-2. Indexed stroke volume remained unchanged. Cardiac function index and global ejection fraction also markedly decreased. Using echocardiography, systolic, diastolic as well as left and right ventricular function parameters worsened. After esmolol cessation, all parameters returned to baseline values. Lactate and microcirculatory parameters did not change while the majority of pro-inflammatory proteins decreased in all patients.

Conclusion: In the very early phase of septic shock, heart rate reduction using fast esmolol titration is associated with an increased risk of hypotension and decreased cardiac index despite maintained adequate tissue perfusion (NCT02068287).

Keywords: Beta-blockers; Inflammation; Norepinephrine; Septic shock.

Conflict of interest statement

The authors disclosed that they received support from Baxter and AMOMED (grant for research) and from INSERM (institutional support). BL received consulting fees from Amomed.

Figures

Fig. 1
Fig. 1
a, b Solid lines are median values while the shaded areas bordered by dotted lines represent the upper and lower quartiles. c, d Points are median values, with the vertical bars indicating the interquartile range. The symbol (*) indicates a significant difference compared to H0 by the Wilcoxon signed-rank test (p < 0.05). M1 = maximum value under esmolol, M2 = last value under esmolol, M3 = first value after esmolol cessation

References

    1. Domizi R, Calcinaro S, Harris S, et al. Relationship between norepinephrine dose, tachycardia and outcome in septic shock: a multicentre evaluation. J Crit Care. 2020;57:185–190. doi: 10.1016/j.jcrc.2020.02.014.
    1. Lee YR, Seth MS, Soney D, et al. Benefits of beta-blockade in sepsis and septic shock: a systematic review. Clin Drug Investig. 2019;39:429–440. doi: 10.1007/s40261-019-00762-z.
    1. Sanfilippo F, Santonocito C, Morelli A, et al. Beta-blocker use in severe sepsis and septic shock: a systematic review. Curr Med Res Opin. 2015;31:1817–1825. doi: 10.1185/03007995.2015.1062357.
    1. Unger M, Morelli A, Singer M, et al. Landiolol in patients with septic shock resident in an intensive care unit (LANDI-SEP): study protocol for a randomized controlled trial. Trials. 2018;19:637. doi: 10.1186/s13063-018-3024-6.
    1. van Loon LM, van der Hoeven JG, Lemson J. Hemodynamic response to beta-blockers in severe sepsis and septic shock: a review of current literature. J Crit Care. 2019;50:138–143. doi: 10.1016/j.jcrc.2018.12.003.
    1. Morelli A, Ertmer C, Westphal M, et al. Effect of heart rate control with esmolol on hemodynamic and clinical outcomes in patients with septic shock: a randomized clinical trial. JAMA. 2013;310:1683–1691. doi: 10.1001/jama.2013.278477.
    1. De Backer D, Annane D. Beta-blockers in septic shock to optimize hemodynamics? We are not sure. Intensive Care Med. 2016;42:1613–1614. doi: 10.1007/s00134-016-4421-5.
    1. Morelli A, Romano SM, Sanfilippo F, et al. Systolic-dicrotic notch pressure difference can identify patients with septic shock at risk of cardiovascular decompensation in case of heart rate reduction. Br J Anaesth. 2020;125:1018–1024. doi: 10.1016/j.bja.2020.05.058.
    1. Dellinger RP, Levy MM, Rhodes A, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med. 2013;39:165–228. doi: 10.1007/s00134-012-2769-8.
    1. Monnet X, Marik P, Teboul JL. Passive leg raising for predicting fluid responsiveness: a systematic review and meta-analysis. Intensive Care Med. 2016;42:1935–1947. doi: 10.1007/s00134-015-4134-1.
    1. De Backer D, Ospina-Tascon G, Salgado D, et al. Monitoring the microcirculation in the critically ill patient: current methods and future approaches. Intensive Care Med. 2010;36:1813–1825. doi: 10.1007/s00134-010-2005-3.
    1. Sakka SG, Koeck H, Meier-Hellmann A. Measurement of indocyanine green plasma disappearance rate by two different dosages. Intensive Care Med. 2004;30:506–509. doi: 10.1007/s00134-003-2091-6.
    1. Morelli A, Donati A, Ertmer C, et al. Microvascular effects of heart rate control with esmolol in patients with septic shock: a pilot study. Crit Care Med. 2013;41:2162–2168. doi: 10.1097/CCM.0b013e31828a678d.
    1. Martin L, Derwall M, Al Zoubi S, et al. The septic heart: current understanding of molecular mechanisms and clinical implications. Chest. 2019;155:427–437. doi: 10.1016/j.chest.2018.08.1037.
    1. Levy B, Buzon J, Kimmoun A. Inotropes and vasopressors use in cardiogenic shock: when, which and how much? Curr Opin Crit Care. 2019;25:384–390. doi: 10.1097/MCC.0000000000000632.
    1. Ince C. Hemodynamic coherence and the rationale for monitoring the microcirculation. Crit Care. 2015;19(Suppl 3):S8. doi: 10.1186/cc14726.

Source: PubMed

3
Subskrybuj